California, US-based Frazier Life Sciences has led a $115 million Series A financing for RQ Biotechnology Ltd, a UK company developing engineered antibody therapies for influenza in order to provide durable protection against serious viral infections. The investor syndicate also includes the venture capital groups Forbion and EQT Life Sciences, alongside founding investor LifeArc Ventures.
TRIMTECH Therapeutics Ltd, which is developing small molecule drugs that target and degrade protein aggregates associated with neurodegenerative diseases, has raised an additional $14 million in seed funding, bringing the total for the round up to $47 million. The financing was led by Johnson & Johnson Innovation and the Business Growth Fund Ltd (BGF), which joined existing investors.
Eli Lilly and Company has broadened an existing partnership with Shanghai, China-based Abbisko Therapeutics Co Ltd to collaborate on the discovery and development of new, but still unidentified medicinal products. In a statement released on 23 June, the US company said the upgraded collaboration is valued at about $1.9 billion.
Research Strategy
Meeting the challenge of Parkinson's disease
By Henri Huttunen
Regenerative Medicine
Tissue repair for venous disease
By Petter Björquist
Commentary
Asia drives trials but its data must travel too
By Femida Gwadry-Sridhar
Research Strategy
How ligand-conjugated vectors can improve treatment
By Lolita Petit
Company News - Financing
$2.1 billion for Isomorphic Labs
Public Health
WHO responds to Ebola outbreak
